Evoq Remedies Shuts Trading Window for FY26 Financial Results

Evoq Remedies Limited will close its trading window from April 1, 2026, reopening 48 hours after the audited financial results for the year ended March 31, 2026, are published.
This procedural step aligns with SEBI's mandate to prevent insider trading ahead of price-sensitive financial disclosures.

What just happened (today’s filing)

Evoq Remedies Limited announced the closure of its trading window for equity shares, effective April 1, 2026. [cite: filing]

This restriction applies to directors, promoters, designated persons, and insiders of the company.

The trading window will remain shut until 48 hours after the company officially publishes its audited financial results for the fiscal year ending March 31, 2026. [cite: filing]

Why this matters

The trading window closure is a standard regulatory mechanism mandated by SEBI to ensure market fairness and prevent potential insider trading.

It prevents individuals with access to non-public information, such as upcoming financial results, from trading the company's shares before the information is disclosed to the public.

This practice promotes transparency and protects the interests of retail investors by leveling the playing field.

The backstory (grounded)

Evoq Remedies Limited, incorporated in 2010 and based in Ahmedabad, is involved in the pharmaceutical business, including trading, manufacturing, and distribution of pharmaceutical products and castor oil.

The company has a history of announcing its audited financial results around April, with its board approving results for the year ended March 31, 2025, on April 10, 2025.

Recent financial performance for FY25 showed revenue of ₹11.76 Cr and a net profit of ₹0.09 Cr, with total assets at ₹50.01 Cr.

What changes now

Shareholders and the market will await the announcement of Evoq Remedies' full-year audited financial results for FY26.

The trading window closure means designated persons cannot transact in the company's stock until the results are out and the window reopens.

This period allows for the formalization and release of the company's annual financial performance, providing insights into its operational and financial health.

Risks to watch

Evoq Remedies faces significant regulatory and compliance challenges, including a SEBI investigation into its financial statements and the utilization of funds from a preferential allotment.

The company has failed to implement mandatory audit trail software and is involved in litigation over a GST demand of ₹655.03 lakhs, alongside income tax disputes.

Auditor concerns have been raised regarding unconfirmed supplier advances totaling ₹1,250.87 lakhs and non-compliant related party transactions, including loans amounting to ₹668.86 lakhs.

There are also issues with unpaid TDS/TCS and a history of mixed financial performance, including operating losses and negative cash flow in recent periods.

Peer comparison

Evoq Remedies operates in a different segment compared to major Indian pharmaceutical giants like Sun Pharmaceutical Industries Ltd., Lupin Limited, and Dr. Reddy's Laboratories Ltd.

While these peers focus heavily on R&D, global generics, and complex formulations, Evoq Remedies' business model revolves around trading, distribution, and manufacturing of pharmaceutical products and castor oil.

Indian pharma majors are increasingly focusing on innovation and global markets, while smaller entities like Evoq Remedies often face challenges in scaling operations and maintaining compliance.

Context metrics (time-bound)

• Evoq Remedies reported revenue of ₹11.76 Crores for the fiscal year ended March 31, 2025. [cite: Trendlyne]
• Net income for FY25 stood at ₹0.09 Crores, reflecting a significant drop in profitability. [cite: Trendlyne]
• As of March 31, 2025, the company's total assets were valued at ₹50.01 Crores. [cite: Trendlyne]

What to track next

Investors will closely monitor the official date of publication for Evoq Remedies' audited financial results for the year ended March 31, 2026.

The content and quality of these results will be crucial, especially given the company's past regulatory and compliance issues.

Subsequent announcements regarding the reopening of the trading window will also be significant indicators.